Frederick G. Vogt - 17 Jan 2023 Form 4 Insider Report for IOVANCE BIOTHERAPEUTICS, INC. (IOVA)

Role
Interim CEO & General Counsel
Signature
/s/ Frederick G. Vogt
Issuer symbol
IOVA
Transactions as of
17 Jan 2023
Net transactions value
-$234,316
Form type
4
Filing time
19 Jan 2023, 15:51:13 UTC
Previous filing
28 Nov 2022
Next filing
06 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IOVA Common Stock Options Exercise $0 +83,325 +4166% $0.000000 85,325 17 Jan 2023 Direct F1
transaction IOVA Common Stock Tax liability $234,316 -36,441 -43% $6.43 48,884 17 Jan 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IOVA Restricted Stock Units Options Exercise $0 -83,325 -33% $0.000000 166,675 17 Jan 2023 Common stock 83,325 Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third of the restricted stock units ("RSUs") issued to the Reporting Person on January 14, 2022, vested on January 14, 2023. The vested RSUs were settled on January 17, 2023.
F2 Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities.
F3 Represents common stock remaining after deducting the common stock withheld for taxes.
F4 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F5 The remaining RSUs will vest in eight equal quarterly installments over the next two years.